V
VR Management, LLC
+ HoldingKRRO
+4.71%
3M Return
$12.910
-0.341 (-2.64%)Zum Schluss
Loading chart…
- High
- 13.549
- Open
- 13.130
- VWAP
- 13.09
- Vol
- 67.37K
- Mkt Cap
- —
- Low
- 12.800
- Amount
- 881.60K
- EV/EBITDA, TTM
- -6.31
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
AI analysis of Korro Bio Inc (KRRO)
holdKorro Bio Inc is not a strong buy at the current price of $12.91 due to its recent performance and financial metrics. The stock has a Relative Strength Index (RSI) of 42.055, indicating it is nearing oversold territory, but it has also seen a significant decline of 41.86% over the past year. While analysts have set price targets ranging from $15 to $23, the company reported a quarterly EPS loss of $1.07, which is concerning. The main risk is the negative net income, which reached -50,042,000 USD in Q4 2025, suggesting ongoing financial challenges.
Bewertungskennzahlen
The current forward P/E ratio for Korro Bio Inc (KRRO) is 0.00, compared to its 5-year average forward P/E of -3.77.
Whales holding KRRO
Event-Zeitleiste
News
8.505-20NASDAQ.COMKorro Bio Selects KRRO-111 for Clinical Development in AAT Deficiency
8.505-19NewsfilterKorro Bio Unveils KRRO-111 for AATD Treatment
9.505-07moomooKORRO BIO INC Reports Quarterly EPS of $-1.69
- 7.505-07moomoo
KORRO BIO INC - ANNOUNCES ZERO COLLABORATION REVENUE FOR Q1 2026
- 7.005-07moomoo
KORRO BIO INC ANTICIPATES CASH RESOURCES TO SUPPORT OPERATIONS THROUGH THE SECOND HALF OF 2028
KRRO FAQ — answered by Alphio AI
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Korro Bio Inc is not a strong buy at the current price of $12.91 due to its recent performance and financial metrics. The stock has a Relative Strength Index (RSI) of 42.055, indicating it is nearing oversold territory, but it has also seen a significant decline of 41.86% over the past year. While analysts have set price targets ranging from $15 to $23, the company reported a quarterly EPS loss of $1.07, which is concerning. The main risk is the negative net income, which reached -50,042,000 USD in Q4 2025, suggesting ongoing financial challenges.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.